Publikationer - Prostatacancer

Utskriftsvänlig sida

Holmberg L, Adolfsson J, Mucci L, Garmo H, Adami HO, Möller H, Johansson JE, Stampfer M. Season of diagnosis and prognosis in breast and prostate cancer. Cancer Causes Control 2009 Jul; 20(5): 663-70.

Andrèn O, Garmo H, Mucci L,& Andersson S-O, Johansson J-E, Fall K. Incidence and mortality of incidental prostate cancer: a Swedish register-based study. Br J Cancer. 2009 Jan 13;100(1):170-3.

Holmström B, Holmberg E, Egevad L, Adolfsson J, Johansson J-E, Hugosson J, Stattin P. Primary vs. Deferred Radical Prostatectomy in The National Prostate Cancer Register (NPCR) of Sweden on behalf of the National Prostate Cancer Register (NPCR) of Sweden. Submitted Nov 200 9.

Stattin P, Holmberg E, Johansson J-E, Holmberg L, Adolfsson J, Hugosson J. Outcomes for men with localized prostate cancer in the National Prostate Cancer Register (NPCR) of Sweden. Accepted for publication JNCI Dec 2009.

Bill-Axelson A, Garmo H, Lambe M, Bratt O, Adolfsson J, Nyberg U, Steineck G, Stattin P. Suicide Risk in Men with Prostate-Specific Antigen-Detected Early Prostate Cancer: A Nationwide Population-Based Cohort Study from PCBaSe Sweden. Eur Urol 2009 Nov 10. [Epub ahead of print].

Hagel E, Garmo H, Bill-Axelson A, Bratt O, Johansson JE, Adolfsson J, Lambe M, Stattin P. PCBaSe Sweden: a register-based resource for prostate cancer research. Scand J Urol Nephrol 2009; 43(5): 342-9.

Carlsson S, Adolfsson J, Bratt O, Johansson JE, Ahlstrand C, Holmberg E, Stattin P, Hugosson J. Nationwide population-based study on 30-day mortality after radical prostatectomy in Sweden. Scand J Urol Nephrol 2009; 43(5): 350-6.

Fall K, Strömberg F, Rosell J, Andrèn O, Varenhorst E; South-East Region Prostate Cancer Group. Reliability of death certificates in prostate cancer patients. Scand J Urol Nephrol 2008; 42(4): 352-7.

Ladjevardi S, Sandblom G, Berglund A, Varenhorst E. Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer. Eur Urol 2009 Mar 10. [Epub ahead of print].

Zheng SL, Sun J, Wiklund F, Gao Z, Stattin P, Purcell LD, Adami HO, Hsu FC, Zhu Y, Adolfsson J, Johansson JE, Turner AR, Adams TS, Liu W, Duggan D, Carpten JD, Chang BL, Isaacs WB, Xu J, Grönberg H. Genetic variants and family history predict prostate cancer similar to prostate-specific antigen Clinical Cancer Research 2009 Feb 1; 15(3): 1105-11.

Liu W, Sun J, Li G, Zhu Y, Zhang S, Kim ST, Sun J, Wiklund F, Wiley K, Isaacs SD, Stattin P, Xu J, Duggan D, Carpten JD, Isaacs WB, Grönberg H, Zheng SL, Chang BL. Association of a Germ-Line Copy Number Variation at 2p24.3 and Risk for Aggressive Prostate Cancer. Cancer Research 2009 Mar 3. [Epub ahead of print]

Lindström S, Adami HO, Bälter K, Xu J, Zheng SL, Sun J, Stattin P, Grönberg H, Wiklund F. Genetic variation in the upstream region of ERG and prostate cancer.Cancer Causes Control. 2009 Feb 10.

Wiklund F, Isaacs SD, Stevens VL, Sun J, Smith S, Pruett K, Romero LM, Wiley KE, Kim ST, Zhu Y, Zhang Z, Hsu FC, Turner AR, Adolfsson J, Liu W, Kim JW, Duggan D, Carpten J, Zheng SL, Rodriguez C, Isaacs WB, Gronberg H, Xu J. Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Human molecular genetics 2009.

Sun J, Zheng SL, Wiklund F, Isaacs SD, Li G, Wiley KE, Kim ST, Zhu Y, Zhang Z, Hsu FC, Turner AR, Stattin P, Liu W, Kim JW, Duggan D, Carpten J, Isaacs W, Gronberg H, Xu J, Chang BL. Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res 2009; 69:10-5.

Wiklund F, Zheng SL, Sun J, Adami HO, Lilja H, Hsu FC, Stattin P, Adolfsson J, Cramer SD, Duggan D, Carpten JD, Chang BL, Isaacs WB, Gronberg H, Xu J. Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. Prostate 2009; 69:419-27.

Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, Nordling S, Häggman M, Andersson S-O, Bratell S, Spångberg A, Palmgren J, Adami H-O, Johansson J-E, for the Scandinavian Prostate Cancer Group Study Number 4. Radical Prostatectomy Versus Watchful Waiting in Localized Prostate Cancer: the Scandinavian Prostate Cancer Group-4 Randomized Trial. JNCI August 20, 2008; 100(16): 1144-1154.

Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, Adami HO, Hsu FC, Zhu Y, Balter K, Kader AK, Turner AR, Liu W, Bleecker ER, Meyers DA, Duggan D, Carpten JD, Chang BL, Isaacs WB, Xu J, Gronberg H. Cumulative Association of Five Genetic Variants with Prostate Cancer. N Engl J Med 2008 Feb 28; 358(9): 910-9.

Sandblom G, Ladjevardi S, Garmo H, Varenhorst E. The impact of prostate-specific antigen level at diagnosis on the relative survival of 28,531 men with localized carcinoma of the prostate. Cancer 2008; Feb 15; 112(4): 813-9.

Stattin P, Holmberg E, Bratt O, Adolfsson J, Johansson JE, Hugosson J. National Prostate Cancer Register. Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. J Urol 2008 Dec; 180(6): 2423-9.

Gudmundsson J, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008; 40: 281-3.

Hsu FC, Lindstrom S, Sun J, Wiklund F, Chen SH, Adami HO, Turner AR, Liu W, Balter K, Kim JW, Stattin P, Chang BL, Isaacs WB, Xu J, Gronberg H, Zheng SL. A multigenic approach to evaluating prostate cancer risk in a systematic replication study. Cancer Genet Cytogenet 2008; 183: 94-8.

Olsson M, Lindström S, Häggkvist B, Adami HO, Bälter K, Stattin P, Ask B, Rane A, Ekström L, Grönberg H. The UGT2B17 gene deletion is not associated with prostate cancer risk. Prostate 2008 Apr 1; 68(5): 571-5.

Sun J, Lange EM, Isaacs SD, Liu W, Wiley KE, Lange L, Gronberg H, Duggan D, Carpten JD, Walsh PC, Xu J, Chang BL, Isaacs WB, Zheng SL. Chromosome 8q24 risk variants in hereditary and non-hereditary prostate cancer patients. Prostate 2008 Apr 1; 68(5): 489-97.

Sun J, Purcell L, Gao Z, Isaacs SD, Wiley KE, Hsu FC, Liu W, Duggan D, Carpten JD, Grönberg H, Xu J, Chang BL, Partin AW, Walsh PC, Isaacs WB, Zheng SL. Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. Prostate 2008 May 15; 68(7): 691-7.

Sun J, Chang BL, Isaacs SD, Wiley KE, Wiklund F, Stattin P, Duggan D, Carpten JD, Trock BJ, Partin AW, Walsh PC, Gronberg H, Xu J, Isaacs WB, Zheng SL. Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate 2008; 68: 1257-62.

Sun J, Zheng SL, Wiklund F, Isaacs SD, Purcell LD, Gao Z, Hsu FC, Kim ST, Liu W, Zhu Y, Stattin P, Adami HO, Wiley KE, Dimitrov L, Sun J, Li T, Turner AR, Adams TS, Adolfsson J, Johansson JE, Lowey J, Trock BJ, Partin AW, Walsh PC, Trent JM, Duggan D, Carpten J, Chang BL, Gronberg H, Isaacs WB, Xu J. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet 2008; 40: 1153-5.

Xu J, Isaacs SD, Sun J, Li G, Wiley KE, Zhu Y, Hsu FC, Wiklund F, Turner AR, Adams TS, Liu W, Trock BJ, Partin AW, Chang B, Walsh PC, Gronberg H, Isaacs W, Zheng S. Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res 2008; 14: 5819-24.

Wiklund F, Lageros YT, Chang E, Balter K, Johansson JE, Adami HO, Gronberg H. Lifetime total physical activity and prostate cancer risk: a population-based case-control study in Sweden. Eur J Epidemiol 2008 ; 23(11): 739-46.

Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andrén O, Bill-Axelson A, Bratt O, Damber JE, Hellström K, Hellström M, Holmberg E, Holmberg L, Hugosson J, Johansson JE, Petterson B, Törnblom M, Widmark A, Stattin P. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Data from the National Prostate Cancer Register in Sweden. Scand J Urol Nephrol 2007; 41(6): 456-77

McKay JD, Kaaks R, Johansson M, Biessy C, Wiklund F, Balter K, Adami HO, Boillot C, Gioia-Patricola L, Canzian F, Stattin P, Gronberg H. Haplotype-based analysis of common variation in the growth hormone receptor gene and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007; 16: 169-73.

Johansson M, McKay JD, Stattin P, Canzian F, Boillot C, Wiklund F, Adami HO, Balter K, Gronberg H, Kaaks R. Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer. Int J Cancer 2007; 120: 539-42.

Johansson M, Van Guelpen B, Hultdin J, Wiklund F, Adami HO, Balter K, Gronberg H, Stattin P. The MTHFR 677C  T polymorphism and risk of prostate cancer: results from the CAPS study. Cancer Causes Control 2007; 18: 1169-74.

Johansson M, McKay JD, Wiklund F, Rinaldi S, Verheus M, van Gils CH, Hallmans G, Balter K, Adami HO, Gronberg H, Stattin P, Kaaks R. Implications for prostate cancer of insulin-like growth factor-I (igf-I) genetic variation and circulating igf-I levels. The Journal of clinical endocrinology and metabolism 2007; 92: 4820-6.

Hedelin M, Chang ET, Wiklund F, Bellocco R, Klint A, Adolfsson J, Shahedi K, Xu J, Adami HO, Gronberg H, Balter KA. Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int J Cancer 2007; 120: 398-405.

Torniainen S, Hedelin M, Autio V, Rasinpera H, Balter KA, Klint A, Bellocco R, Wiklund F, Stattin P, Ikonen T, Tammela TL, Schleutker J, Gronberg H, Jarvela I. Lactase persistence, dietary intake of milk, and the risk for prostate cancer in Sweden and Finland. Cancer Epidemiol Biomarkers Prev 2007; 16: 956-61.

Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L, Wiklund F, Robbins C, Isaacs SD, Cheng Y, Li G, Sun J, Chang BL, Marovich L, Wiley KE, Balter K, Stattin P, Adami HO, Gielzak M, Yan G, Sauvageot J, Liu W, Kim JW, Bleecker ER, Meyers DA, Trock BJ, Partin AW, Walsh PC, Isaacs WB, Gronberg H, Xu J, Carpten JD. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007; 99: 1836-44.

Lindstrom S, Adami HO, Balter KA, Xu J, Zheng SL, Stattin P, Gronberg H, Wiklund F. Inherited variation in hormone-regulating genes and prostate cancer survival. Clin Cancer Res 2007; 13: 5156-61.

Fall K, Garmo H, Andrén O, Bill-Axelson A, Adolfsson J, Adami HO, Johansson JE, Holmberg L for the Scandinavian Prostate Cancer Group Study No 4. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007; 99: 526-532.

Amundadottir LT et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006; 38(6): 652-8.

Hedelin M, Klint A, Chang ET, Bellocco R, Johansson JE, Andersson SO, Heinonen SM, Adlercreutz H, Adami HO, Gronberg H, Balter KA: Dietary phytoestrogen, serum enterolactone and risk of prostate cancer: the cancer prostate Sweden study (Sweden). Cancer Causes Control 2006; 17(2): 169-80.

Shahedi K, Lindstrom S, Zheng SL, Wiklund F, Adolfsson J, Sun J, Augustsson-Balter K, Chang BL, Adami HO, Liu W, Gronberg H, Xu J. Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer 2006; 119(3): 668-72.

Sun J, Wiklund F, Hsu FC, Balter K, Zheng SL, Johansson JE, Chang B, Liu W, Li T, Turner AR, Li L, Li G, Adami HO, Isaacs WB, Xu J, Gronberg H. Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2006; 15(3): 480-5.

Thellenberg-Karlsson C, Lindstrom S, Malmer B, Wiklund F, Augustsson-Balter K, Adami HO, Stattin P, Nilsson M, Dahlman-Wright K, Gustafsson JA, Gronberg H: Estrogen receptor beta polymorphism is associated with prostate cancer risk. Clin Cancer Res 2006; 12(6): 1936-41.

Lindstrom S, Zheng SL, Wiklund F, Jonsson B-A, Adami H-O, Augustsson Balter K, Brookes AJ, Sun J, Chang B-L, Liu W, Li G, Isaacs WB, Adolfsson J, Gronberg H, Xu J: Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway. The Prostate 2006 Dec 1; 66(16): 1729-43.

Lindstrom S, Wiklund F, Adami HO, Balter KA, Adolfsson J,Gronberg H. Germ-line genetic variation in the key androgen-regulating genes androgen receptor, cytochrome P450, and steroid-5-alpha-reductase type 2 is important for prostate cancer development. Cancer Res. 2006 Nov 15; 66(22): 11077-83.

Andersson P, Varenhorst E, Söderkvist P. Androgen receptor and vitamin D receptor gene polymorphisms and prostate cancer risk. Eur J Cancer 2006; 42(16): 2833-7.

Sennfält K, Carlsson P, Varenhorst E. Diffusion and economic consequences of health technologies in prostate cancer care in Sweden 1998-2003. Eur Urol 2006; 49(6): 1028-34.

Holmberg L, Bill-Axelson A, Garmo H, Palmgren J, Norlén BJ, Adami HO, Johansson JE and the SPCG-4 study group. Prognostic markers under watchful waiting and radical prostatectomy. Hematol Oncol Clin North Am 2006; 20: 845-855.

Varenhorst E, Garmo H, Holmberg L, Stattin P, Johansson J-E. Prostatacancer i Sverige 1998-2003. Drastisk förändring av sjukdomspanoramat. Läkartidningen 2006; 5(103): 285-8. Läs artikeln här.

Lindstrom S, Wiklund F, Jonsson BA, Adami HO, Balter K, Brookes AJ, Xu J, Zheng SL, Isaacs WB, Adolfsson J, Gronberg H. . Comprehensive genetic evaluation of common E-cadherin sequence variants and prostate cancer risk: strong confirmation of functional promoter SNP. Hum Genet 2005; 118(3-4): 339-47.

Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S, Spångberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlén BJ, Johansson JE; Scandinavian Prostate Cancer Group Study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352; 1977-1984.

Stattin P, Johansson R, Lodnert R, Andren O, Bill-Axelsson A, Bratt O, et al. Geogra-phical variation in incidence of prostate cancer in Sweden. Scand J Urol Nephrol 2005; 39(5): 372-9.

Xu J, Lowey J, Wiklund F, Sun J, Lindmark F, Hsu FC, et al. The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14(11 Pt 1): 2563-8.

Lindmark F, Zheng SL, Wiklund F, Balter KA, Sun J, Chang B, et al. Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk. Br J Cancer 2005; 93(4): 493-7.

Sun J, Wiklund F, Zheng SL, Chang B, Balter K, Li L, et al. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 2005; 97(7): 525-32.

Aus G, Robinson D, Rosell J, Sandblom G, Varenhorst E. Survival in prostate carcinoma - outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden. Cancer 2005; 103(5): 943-51.

Chang ET, Hedelin M, Adami HO, Gronberg H, Balter KA. Alcohol drinking and risk of localized versus advanced and sporadic versus familial prostate cancer in Sweden. Cancer Causes Control 2005; 16(3): 275-84.

Varenhorst E, Garmo H, Holmberg L, Adolfsson J, Damber JE, Hellström M, Hugosson J, Lundgren R, Stattin P, Törnblom M, Johansson JE. The national prostate cancer register in Sweden 1998-2002: Trends in incidence, treatment and survival. Scand J Urology and Nephrology 2005; 39: 117-123.

Sennfält K. Economic studies of health technology changes in prostate cancer care. Linköping: Center for Medical Technology Assessment Department of Healt and Society Linköping University, 2005.

Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO. Natural history of early, localized prostate cancer. JAMA 2004; 291: 2713-2719.

Sandblom G, Varenhorst E. Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital. BJU Int 2004; 93(6): 889-90.

Jonsson BA, Adami HO, Hagglund M, Bergh A, Goransson I, Stattin P, et al. -160C/A polymorphism in the E-cadherin gene promoter and risk of hereditary, familial and sporadic prostate cancer. Int J Cancer 2004; 109(3): 348-52.

Sandblom G, Varenhorst E, Lofman O, Rosell J, Carlsson P. Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. Eur Urol 2004; 46(6): 717-23; discussion 724.

Sennfält K, Sandblom G, Carlsson P, Varenhorst E. Costs and effects of prostate cancer screening in Sweden - a 15-year follow-up of a randomized trial. Scand J Urol Nephrol 2004; 38(4): 291-8.

Sennfält K, Carlsson P, Sandblom G, Varenhorst E. The estimated economic value of the welfare loss due to prostate cancer pain in a defined population. Acta Oncol 2004; 43(3): 290-6.

Wiklund F, Jonsson BA, Brookes AJ, Stromqvist L, Adolfsson J, Emanuelsson M, et al. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin Cancer Res 2004; 10(21): 7150-6.

Lindmark F, Zheng SL, Wiklund F, Bensen J, Balter KA, Chang B, et al. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst 2004; 96(16): 1248-54.

Lindmark F, Jonsson BA, Bergh A, Stattin P, Zheng SL, Meyers DA, Xu J, Gronberg H. Analysis of the macrophage scavenger receptor 1 gene in Swedish hereditary and sporadic prostate cancer. Prostate 2004; 59(2): 132-40.

Sun J, Hedelin M, Zheng SL, Adami HO, Bensen J, Augustsson-Balter K, et al. Interleukin-6 sequence variants are not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2004; 13(10): 1677-9.

Sandblom G, Carlsson P, Sennfalt K, Varenhorst E. A population-based study of pain and quality of life during the year before death in men with prostate cancer. Br J Cancer 2004; 90(6): 1163-8.

Chang ET, Hedelin M, Adami HO, Gronberg H, Balter KA. Re: Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst 2004; 96(14): 1108; author reply 1108-9.

Zheng SL, Augustsson-Balter K, Chang B, Hedelin M, Li L, Adami HO, et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res 2004; 64(8): 2918-22.

Bill-Axelson A, Holmberg L, Norlén BJ, Busch C, Norberg M. No increased prostate cancer incidence after negative transrectal ultrasound guided multiple biopsies in men with increased prostate specific antigen and/or abnormal digital rectal examination. J Urol 2003; 170: 1180-3.

Aus G, Nordenskjold K, Robinson D, Rosell J, Varenhorst E. Prognostic factors and survival in node-positive (N1) prostate cancer-a prospective study based on data from a Swedish population-based cohort. Eur Urol 2003; 43(6): 627-31.

Sennfalt K, Carlsson P, Thorfinn J, Frisk J, Henriksson M, Varenhorst E. Technological changes in the management of prostate cancer result in increased healthcare costs--a retrospective study in a defined Swedish population. Scand J Urol Nephrol 2003; 37(3): 226-31.

Sandblom G, Dufmats M, Olsson M, Varenhorst E. Validity of a population-based cancer register in Sweden - an assessment of data reproducibility in the South-East Region Prostate Cancer Register. Scand J Urol Nephrol 2003; 37(2): 112-9.

Stattin P, Johansson R, Damber JE, Hellstrom M, Hugosson J, Lundgren R, et al. Non-systematic screening for prostate cancer in Sweden - survey from the National Prostate Cancer Registry. Scand J Urol Nephrol 2003; 37(6): 461-5.

Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlén BJ, Holmberg L. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002; 347: 790-796.

Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Häggman M, Andersson SO, Spångberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE, Norlén BJ. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002, 347: 781-789.

Sandblom G, Holmberg L, Damber JE, Hugosson J, Johansson JE, Lundgren R, Mattsson E, Nilsson J, Varenhorst E. Prostate-specific antigen as surrogate for characterizing prostate cancer subgroups. Scand J Urol Nephrol 2002; 36(2): 106-112.

Sandblom G, Holmberg L, Damber JE, Hugosson J, Johansson JE, Lundgren R, Mattsson E, Nilsson J, Varenhorst E. Prostate-Specific Antigen for prostate cancer staging in a population-based register. Scand J Urol Nephrol 2002; 36(2): 99-105.

Egevad L. Reproducibility of Gleason grading of prostate cancer can be improved by the use of reference images. Urology 2001; 57(2): 291-5.

Sandblom G, Carlsson P, Sigsjo P, Varenhorst E. Pain and health-related quality of life in a geographically defined population of men with prostate cancer. Br J Cancer 2001; 85(4): 497-503.

Sandblom G. Diagnosis, management, quality of life, and long-term survival in prostate cancer patients. Medical Dissertation No 664, Linköping University, 2001.

Sandblom G, Dufmats M, Nordenskjold K, Varenhorst E. Prostate carcinoma trends in three counties in Sweden 1987-1996: results from a population-based national cancer register. South-East Region Prostate Cancer Group. Cancer 2000; 88(6): 1445-53.

Helgesen F, Andersson SO, Gustafsson O, Varenhorst E, Gobén B, Carnock S, Sehlstedt L, Carlsson P, Holmberg L, Johansson JE. Follow-up of prostate cancer patients by on-demand contacts with a specialist nurse. A randomized study. Scand J Urol Nephrol 2000; 34: 55-61.

Sandblom G, Mattson E, Damber J-E, Johnasson J-E, Lundgren R, Varenhorst E. Prostate cancer registration in four regions 1996. Differences in incidence, age structure and management. Scand J Urol Nephrol. 1999; 33(5): 306-311.

Abstract

Pär Stattin. Mortalitet efter operation, strålning och monitorering i uppföljningsstudien. Del av symposium om aktiv monitorering, moderator Ola Bratt. Läkarstämman, November 2008 Göteborg.

Anna Bill Axelsson. Risk för suicid vid prostatacancer. Muntlig presentation. Läkarstämman November 2008, Göteborg.

Pär Stattin et al. PCBaSe Sweden. Uppföljning och nationella länkningar ger unik databas för prostatacancerstudier. Poster Läkarstämman November 2008 Göteborg.

Pär Stattin et al. Surveillance for localized prostate cancer. A population-based study in the National Prostate Cancer Register (NPCR) in Sweden. Poster AACR/ASCO, San Francisco Feb 2008.

Sigrid Carlsson et al. Nationell populationsbaserad studie av perioperativ mortalitet i samband med prostatectomi. Urologisektionen, Läkarstämman, November Stockholm 2007.

Pär Stattin et al. Duaration av aktiv monitorering/expektans som primärbehandling av loklaiserad pros-tatacancer. Populationsbaserad studie i Nationella prostatacancerregis-tret (NPCR). Urologisektionen, Läkarstämman, November Stockholm 2007.

Jan Adolfsson et al. Nationella prostatacancerregitret – Uppföljning av kliniska data och primärbehandling 1996-2005. Urologisektionen, Läkarstämman, November Stockholm 2007.

Stattin P, Holmberg E, Hugosson J. Duration of active monitoring as primary treatment in localized prostate cancer. A population-based study of the National prostate cancer register (NPCR) in Sweden. AUA Anaheim, CA, 2007.

Ladjevardi S, Sandblom G, Garmo H, Varenhorst E. Relativ överlevnad hos män med potentiellt kurabel prostatacancer. Svenska Läkarsällskapets Riksstämma, Göteborg, November 2006.

Sandblom G, Löfman O, Rosell J, Ahlstrand C, Robinson D, Hellström L, Varenhorst E. Geografiska variationer i incidensen av prostatacancer i Kalmars och Östergötlands Län- en analys med geografiskt informationssystem (GIS). Svenska Läkarsällskapets Riksstämma, Göteborg, November 2006.

Sandblom D, Andren O, Fall K, Varenhorst E, Robinson D, Johansson J-E, Andersson S-O. Betydelse av tumörvolym och Gleasonsumma – en populationsbaserad uppföljningsstudie av T1 a-b prostatacancer. Svenska Läkarsällskapets Riksstämma, Göteborg, November 2006.

Hjelmgren J, Sennfält K. Behandling av lokalt avancerad prostatacancer. Svenska Läkarsällskapets Riksstämma November 2006.

Johansson R, Lodnert R, Andrén O, Stattin P, Bill-Axelsson A, Bratt O, et al. Stora skillnader i icke-systematisk screening för prostatacancer i Sverige: Studie från Nationella prostatacancerregistret. Svenska Läkarsällskapets Riksstämma, November 2004.

Robinson D, Aus G, Rosell J, Sandblom G, Varenhorst E. Långtidsöverlevnad vid prostatacancer - en populationsbaserad studie. Svenska Läkarsällskapets Riksstämma, November 2004.

Hugosson J, Bratt O, Damber J-E, Hellström M, Holmberg E, Johansson J-E, et al. Nationellt Uppföljningsregister för män med lokaliserad Prostatacancer (PC). Svenska Läkarsällskapets Riksstämma, November 2004.

Robinsson D, Bak J, Gorecki T, Herder A, Rosell J, Varenhorst E. Sjukdomsspecifik mortalitet och prognostiska faktorer vid prostatacancer kategori T1a och T1b. Svenska Läkarsällskapets Riksstämma, November 2003.

Stattin P, Johansson R, Damber J-E, Hellström M, Hugosson J, Lundgren R, et al. Icke-systematisk screening för prostatacancer. Studie i nationella prostatacancerregistret. Svenska Läkarsällskapets Riksstämma, November 2003.

Sandblom G, Dufmats M, Olsson M, Varenhorst E. Reproducerbarhet av data i Sydöstra Regionens Prostatacancerregister. Svenska Läkaresällskapets Riksstämma, November 2001.

Johansson J-E, Gustavsson O, Hellström M, Holmberg E, Holmberg L, Hugosson J, Lundgren R, Stattin P, Varenhorst E. Rekordhög incidensökning av prostatacancer i Sverige under 1999. Rapport från Nationella Prostatacancerregistret 1996-1999. Svenska Läkaresällskapets Riksstämma, November 2001.

Pilebro B, Damber J-E, Damber L, Johansson R, Stattin P. Varför togs PSA-prov som ledde fram till prostatacancerdiagnos? Svenska Läkaresällskapets Riksstämma, November 2001.

Adolfsson J, Marké L-Å. PSA-användning I Sverige. Svenska Läkaresällskapets Riksstämma, November 2001.

Johansson J-E, Gustavsson O, Hellström M, Holmberg E, Holmberg L, Hugosson J, Lundgren R, Stattin P, Varenhorst E. Nationella prostatacancerregistret 1996-1998. Stora regionala skillnader i incidens och primärbehandling. Svenska Läkaresällskapets Riksstämma, November 2000.

Johansson J-E. Stora geografiska variationer i incidens och primärbehandling vid prostatacancer i Sverige. Socialstyrelsens Kvalitetsregisterdagar, Oktober 2000.